expressed her excitement about the partnership, stating "We are pleased to collaborate with Greenwich LifeSciences on this important immunotherapy study. With a focus on HER2+ high-risk patients who have not achieved a pathologic complete response (pCR), but also ...
expressed her excitement about the partnership, stating "We are pleased to collaborate with Greenwich LifeSciences on this important immunotherapy study. With a focus on HER2+ high-risk patients who have not achieved a pathologic complete response (pCR), but also...